Amgen’s IMDYLLTRA Wins EU Approval for Small Cell Lung Cancer
THOUSAND OAKS, Calif., June 1, 2026 Amgen has secured a major regulatory milestone with the European Commission approval of...
neurological disorders
Advertisement
NeuroPace Wins FDA Approval for AI-Powered Epilepsy Tool
MOUNTAIN VIEW, Calif., May 29, 2026 NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of...
Sanofi’s Venglustat Gains FDA Priority Review for GD3
PARIS, France, May 28, 2026 Sanofi has achieved a major regulatory milestone with the U.S. Food and Drug Administration...
Persistence Market Research Predicts CGRP Inhibitors Market to Reach $12.5B
London, United Kingdom, May 25, 2026 The global market for CGRP inhibitors, one of the fastest-growing classes of migraine...
Encoded Therapeutics Showcases ETX101 Data at ASGCT
SOUTH SAN FRANCISCO, Calif., April 27, 2026 Encoded Therapeutics announced its participation in the 29th Annual Meeting of the...
Advertisements
Rapport, Tenacia Partner to Develop RAP-219 in China
Boston, USA & Shanghai, China – March 9, 2026 Rapport Therapeutics and Tenacia Biotechnology have announced a strategic collaboration...
NervGen Aligns Capital Strategy to Advance Regenerative Clinical R&D
VANCOUVER, Canada — December 12, 2025 — NervGen Pharma Corp., a clinical-stage biopharmaceutical company developing regenerative therapies for neurological...
FDA Fast Track Granted to CS-1103 for Meth Intoxication
CAMBRIDGE, Mass., Sept. 30, 2025 — Clear Scientific, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Biogen to Acquire Alcyone Therapeutics to Enhance Delivery Portfolio
September 18, 2025 — Cambridge, Massachusetts Biogen has announced the acquisition of Alcyone Therapeutics, a Massachusetts-based biotech company specializing...
Advertisement
